Feline Osteoarthritis Treatment Market report gives a comprehensive outlook on across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on global market gives historical, current, and future market sizes (US$ Mn) of drug class, formulation type, distribution channel and geographic regions. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of global market.
Feline osteoarthritis is an autoimmune disorder caused by infection, injury, or degenerative problems in the joints. Feline osteoarthritis mainly caused due to the genetic changes, injury, abnormal joint loading, obesity, and acromegaly. The symptoms associated with the feline osteoarthritis include pain, swollen joints, loss of muscle mass, and limited movement among others. Diagnosis of feline osteoarthritis is difficult and it cannot be diagnosed with normal symptoms. However, the disease can be identified by the Radiography (X-rays) which can reveal the joint abnormalities and bony growths in feline. Feline osteoarthritis can be treated with physical exercise, anti-inflammatories, and surgical treatment among others. In April 2017, Zoetis Inc. acquired Nexvet Biopharma Plc for strengthening its pipeline products for chronic pain management in cats and dogs